WO2000061171A3 - Uses of mammalian ox2 protein and related reagents - Google Patents

Uses of mammalian ox2 protein and related reagents Download PDF

Info

Publication number
WO2000061171A3
WO2000061171A3 PCT/US2000/009719 US0009719W WO0061171A3 WO 2000061171 A3 WO2000061171 A3 WO 2000061171A3 US 0009719 W US0009719 W US 0009719W WO 0061171 A3 WO0061171 A3 WO 0061171A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammalian
protein
related reagents
methods
reagents
Prior art date
Application number
PCT/US2000/009719
Other languages
French (fr)
Other versions
WO2000061171A2 (en
WO2000061171A9 (en
Inventor
Robert M Hoek
Jonathan D Sedgwick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to EP00923257A priority Critical patent/EP1171154A2/en
Priority to AU43413/00A priority patent/AU4341300A/en
Priority to MXPA01010480A priority patent/MXPA01010480A/en
Priority to JP2000610503A priority patent/JP2002541210A/en
Priority to CA002369454A priority patent/CA2369454A1/en
Publication of WO2000061171A2 publication Critical patent/WO2000061171A2/en
Publication of WO2000061171A3 publication Critical patent/WO2000061171A3/en
Publication of WO2000061171A9 publication Critical patent/WO2000061171A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

Compositions and methods for using mammalian ligand OX2 to treat an abnormal physiological condition in an individual. The methods comprise administering a therapeutically effective amount of OX2 alone, or in combination with other therapeutic reagents; or an OX2 antagonist.
PCT/US2000/009719 1999-04-13 2000-04-12 Uses of mammalian ox2 protein and related reagents WO2000061171A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00923257A EP1171154A2 (en) 1999-04-13 2000-04-12 Uses of mammalian ox2 protein and related reagents
AU43413/00A AU4341300A (en) 1999-04-13 2000-04-12 Novel uses of mammalian ox2 protein and related reagents
MXPA01010480A MXPA01010480A (en) 1999-04-13 2000-04-12 Novel uses of mammalian ox2 protein and related reagents.
JP2000610503A JP2002541210A (en) 1999-04-13 2000-04-12 Novel use of mammalian OX2 protein and related reagents
CA002369454A CA2369454A1 (en) 1999-04-13 2000-04-12 Uses of mammalian ox2 protein and related reagents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29082599A 1999-04-13 1999-04-13
US09/290,825 1999-04-13

Publications (3)

Publication Number Publication Date
WO2000061171A2 WO2000061171A2 (en) 2000-10-19
WO2000061171A3 true WO2000061171A3 (en) 2001-01-25
WO2000061171A9 WO2000061171A9 (en) 2002-01-03

Family

ID=23117713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009719 WO2000061171A2 (en) 1999-04-13 2000-04-12 Uses of mammalian ox2 protein and related reagents

Country Status (7)

Country Link
EP (1) EP1171154A2 (en)
JP (1) JP2002541210A (en)
AR (1) AR023464A1 (en)
AU (1) AU4341300A (en)
CA (1) CA2369454A1 (en)
MX (1) MXPA01010480A (en)
WO (1) WO2000061171A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030835A2 (en) 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
GB202115803D0 (en) 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
WO2023214387A1 (en) 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
WO2023214388A1 (en) 2022-05-06 2023-11-09 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021450A1 (en) * 1995-12-08 1997-06-19 Brigham And Women's Hospital, Inc. Ox-2 costimulatory molecule
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
WO1999024565A1 (en) * 1997-11-07 1999-05-20 Transplantation Technologies Inc. Methods and compositions for immunomodulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
WO1997021450A1 (en) * 1995-12-08 1997-06-19 Brigham And Women's Hospital, Inc. Ox-2 costimulatory molecule
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
WO1999024565A1 (en) * 1997-11-07 1999-05-20 Transplantation Technologies Inc. Methods and compositions for immunomodulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NI J ET AL: "An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant which prolongs allograft survival.", FASEB JOURNAL, vol. 13, no. 5 PART 2, 15 March 1999 (1999-03-15), Annual Meeting of the Professional Research Scientists on Experimental Biology 99;Washington, D.C., USA; April 17-21, 1999, pages A983, XP000960581, ISSN: 0892-6638 *
RAGHEB RAFIK ET AL: "Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2.", IMMUNOLOGY LETTERS, vol. 68, no. 2-3, 1 June 1999 (1999-06-01), pages 311 - 315, XP000960642, ISSN: 0165-2478 *

Also Published As

Publication number Publication date
MXPA01010480A (en) 2002-03-27
AR023464A1 (en) 2002-09-04
WO2000061171A2 (en) 2000-10-19
CA2369454A1 (en) 2000-10-19
WO2000061171A9 (en) 2002-01-03
JP2002541210A (en) 2002-12-03
EP1171154A2 (en) 2002-01-16
AU4341300A (en) 2000-11-14

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP1820862A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
WO2002004421A3 (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
WO2002015920A3 (en) Treatment of hyperproliferative diseases
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
WO2001017558A3 (en) Novel uses of mammalian ccr6 receptors and related reagents
WO2001034641A3 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
WO1999002143A3 (en) Medicament comprising adenosine
AU2003290015A1 (en) Mastitis treatment
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
EP1099439A3 (en) Use of apo B secretion/MTP inhibitors
CA2325282A1 (en) Use of apo b secretion/mtp inhibitors
AU8028600A (en) Methods, pharmaceutical and therapeutic compositions for administering adenosine
WO2001041771A3 (en) Transdermal system containing acetylsalicylic acid for treatment of migraine
WO2001085209A3 (en) Treating t-cell mediated diseases by modulating dr6 activity
GB0128071D0 (en) Medicament
EP1584333A3 (en) Use of acetylcoenzime A inhibitors for treating Alzheimer's disease
AU7370798A (en) Compositions and methods of therapy for igf-i-responsive conditions
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
WO2004002399A3 (en) Use of gaba-c receptor antagonists for the treatment of myopia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2369454

Country of ref document: CA

Ref country code: CA

Ref document number: 2369454

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 610503

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010480

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000923257

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-4, SEQUENCE LISTING, ADDED

WWP Wipo information: published in national office

Ref document number: 2000923257

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000923257

Country of ref document: EP